Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001552066 | SCV001772686 | uncertain significance | not provided | 2020-09-24 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001552066 | SCV003498880 | uncertain significance | not provided | 2022-09-06 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 1219 of the PCDH15 protein (p.Lys1219Arg). This variant is present in population databases (rs763978654, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with PCDH15-related conditions. ClinVar contains an entry for this variant (Variation ID: 1191114). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004952978 | SCV005470191 | uncertain significance | Inborn genetic diseases | 2024-07-17 | criteria provided, single submitter | clinical testing | The c.3656A>G (p.K1219R) alteration is located in exon 27 (coding exon 26) of the PCDH15 gene. This alteration results from a A to G substitution at nucleotide position 3656, causing the lysine (K) at amino acid position 1219 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001832752 | SCV002094884 | uncertain significance | Usher syndrome type 1F | 2020-03-17 | no assertion criteria provided | clinical testing |